'First' stem cell treatment approved in Canada
This article was originally published in Scrip
Executive Summary
Osiris Therapeutics' Prochymal (remestemcel-L) for treating acute graft-vs-host disease (GvHD) has become the world's first manufactured stem cell therapy to win regulatory approval, claims the firm. Health Canada has approved the product for managing acute GvHD in children who fail to respond to steroids.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.